{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:52:39Z","timestamp":1791312759512,"version":"4.3.1"},"reference-count":51,"publisher":"Georg Thieme Verlag KG","issue":"06","funder":[{"name":"Bristol Myers Squibb\/Pfizer Alliance"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with acute venous thromboembolism (VTE) in the setting of transient provoking factors are typically treated with short-term anticoagulation. However, the risk of recurrence may be increased in the presence of enduring risk factors. In such patients, the optimal duration of treatment remains uncertain. HI-PRO is a single-center, double-blind randomized trial. Patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) following a major provoking factor, including major surgery or major trauma, who completed at least 3 months of standard-dose therapeutic anticoagulation and have at least one enduring risk factor (such as obesity or heart failure) will be considered for inclusion. Patients will be randomized to apixaban 2.5\u2009mg twice daily or placebo for 12 months. The primary efficacy outcome will be symptomatic recurrent VTE\u2014a composite of DVT and\/or PE at 12 months after randomization. Secondary efficacy outcomes include a composite of death due to cardiovascular causes, nonfatal myocardial infarction, stroke or systemic embolism, major adverse limb events, or coronary or peripheral ischemia requiring revascularization at 12 months, and individual components of these outcomes. The primary safety outcome is major bleeding according to the International Society on Thrombosis and Haemostasis definition. The study plans to enroll 600 patients (300 per arm) to have 80% power for detecting a 75% relative risk reduction in the primary outcome. Active recruitment began in March 2021. HI-PRO will provide clinically meaningful data on whether patients with provoked VTE and enduring risk factors have fewer adverse clinical outcomes if prescribed low-intensity extended-duration anticoagulation.<\/jats:p>","DOI":"10.1055\/a-1646-2244","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T23:52:50Z","timestamp":1631836370000},"page":"1061-1070","source":"Crossref","is-referenced-by-count":13,"title":["Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial"],"prefix":"10.1055","volume":"122","author":[{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut, United States"},{"name":"Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Hogan","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth B.","family":"Morrison","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fanikos","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Department of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Campia","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana M.","family":"Barns","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana B.","family":"Pfeferman","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E.","family":"Snyder","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candrika D.","family":"Khairani","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"},{"name":"Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,10,31]]},"reference":[{"issue":"09","key":"ref1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"A M Wendelboe","year":"2016","journal-title":"Circ Res"},{"issue":"09","key":"ref2","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"S S Virani","year":"2020","journal-title":"Circulation"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.amjmed.2012.07.025","article-title":"Hospital costs of acute pulmonary embolism","volume":"126","author":"J Fanikos","year":"2013","journal-title":"Am J Med"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0041-1722964","article-title":"Determinants and management of the post-pulmonary embolism syndrome","volume":"42","author":"G JAM Boon","year":"2021","journal-title":"Semin Respir Crit Care Med"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.blre.2014.07.003","article-title":"The post-PE syndrome: a new concept for chronic complications of pulmonary embolism","volume":"28","author":"F A Klok","year":"2014","journal-title":"Blood Rev"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/ATVBAHA.108.162545","article-title":"The epidemiology of venous thromboembolism in the community","volume":"28","author":"J A Heit","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref7","first-page":"1","article-title":"Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US","volume":"106","author":"J A Heit","year":"2005","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21859\/ijcp-010301","article-title":"Updates on advanced therapies for acute pulmonary embolism","volume":"1","author":"B Bikdeli","year":"2016","journal-title":"Int J Cardiovasc Pract"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.amjcard.2015.07.068","article-title":"National trends in pulmonary embolism hospitalization rates and outcomes for adults aged \u226565 years in the United States (1999 to 2010)","volume":"116","author":"K E Minges","year":"2015","journal-title":"Am J Cardiol"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2015.10.060","article-title":"Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE registry","volume":"67","author":"D Jim\u00e9nez","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2213-2600(19)30354-6","article-title":"Trends in mortality related to pulmonary embolism in the European region, 2000-15: analysis of vital registration data from the WHO Mortality Database","volume":"8","author":"S Barco","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"04","key":"ref12","first-page":"756","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"A T Cohen","year":"2007","journal-title":"Thromb Haemost"},{"issue":"18","key":"ref13","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"130","author":"S R Kahn","year":"2014","journal-title":"Circulation"},{"issue":"22","key":"ref14","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa032274","article-title":"Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism","volume":"350","author":"V Pengo","year":"2004","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2017.07.026","article-title":"Epidemiology of the post-thrombotic syndrome","volume":"164","author":"J P Galanaud","year":"2018","journal-title":"Thromb Res"},{"issue":"08","key":"ref16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"ref17","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"J I Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"07","key":"ref20","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"C Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0039-3400302","article-title":"Broadening the categories of patients eligible for extended venous thromboembolism treatment","volume":"120","author":"M Schindewolf","year":"2020","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1160\/TH14-04-0396","article-title":"Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests","volume":"113","author":"P Prandoni","year":"2015","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.10516","article-title":"The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients","volume":"92","author":"P Prandoni","year":"2007","journal-title":"Haematologica"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"S K Kakkos","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"23","key":"ref25","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.118.036548","article-title":"Let's stop dichotomizing venous thromboembolism as provoked or unprovoked","volume":"138","author":"I E Albertsen","year":"2018","journal-title":"Circulation"},{"issue":"03","key":"ref26","first-page":"645","article-title":"Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study","volume":"114","author":"J I Weitz","year":"2015","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/bloodadvances.2018017160","article-title":"Risk of recurrent venous thromboembolism according to baseline risk factor profiles","volume":"2","author":"M H Prins","year":"2018","journal-title":"Blood Adv"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.thromres.2015.02.032","article-title":"Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis","volume":"135","author":"D M Sobieraj","year":"2015","journal-title":"Thromb Res"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"S Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"P A Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"13","key":"ref33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"J Simes","year":"2014","journal-title":"Circulation"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"P C Austin","year":"2016","journal-title":"Circulation"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"l4686","DOI":"10.1136\/bmj.l4686","article-title":"Minimizing recurrent venous thromboembolism","volume":"366","author":"B Bikdeli","year":"2019","journal-title":"BMJ"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"N S Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"D Farge","year":"2019","journal-title":"Lancet Oncol"},{"issue":"08","key":"ref39","first-page":"CD001367","article-title":"Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism","volume":"2014","author":"S Middeldorp","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2018.08.014","article-title":"Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days","volume":"206","author":"J A Nieto","year":"2018","journal-title":"Am Heart J"},{"issue":"25","key":"ref41","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1161\/CIRCULATIONAHA.114.010456","article-title":"Duration of anticoagulation for venous thromboembolic events","volume":"130","author":"N R Smilowitz","year":"2014","journal-title":"Circulation"},{"issue":"15","key":"ref42","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa022157","article-title":"An association between atherosclerosis and venous thrombosis","volume":"348","author":"P Prandoni","year":"2003","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(07)61745-0","article-title":"Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study","volume":"370","author":"H T S\u00f8rensen","year":"2007","journal-title":"Lancet"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","article-title":"Cardiovascular risk factors associated with venous thromboembolism","volume":"4","author":"J Gregson","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"19","key":"ref45","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1161\/CIRCULATIONAHA.110.951236","article-title":"Venous thromboembolism and atherothrombosis: an integrated approach","volume":"121","author":"G Piazza","year":"2010","journal-title":"Circulation"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/1076029613517166","article-title":"Risk assessment to predict arterial and venous events in patients undergoing percutaneous coronary intervention","volume":"20","author":"M Vardi","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"issue":"19","key":"ref47","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"T L Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"08","key":"ref48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"S Schulman","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"ref49","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"ref50","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"P M Ridker","year":"2003","journal-title":"N Engl J Med"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis","volume":"345","author":"G Agnelli","year":"2001","journal-title":"N Engl J Med"},{"issue":"01","key":"ref52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2015.7046","article-title":"Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial","volume":"314","author":"F Couturaud","year":"2015","journal-title":"JAMA"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1646-2244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T14:45:33Z","timestamp":1660142733000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1646-2244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":51,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2022,7,4]]},"published-print":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1646-2244","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,16]]},"published":{"date-parts":[[2021,9,16]]}}}